Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MicroConstants, a GLP-compliant contract research organisation (CRO) specialising in bioanalytical and pharmacokinetic analysis, has acquired access to a new nanosizing technology that transforms water insoluble compounds into nanoparticles, making formulation preparation and dosing for toxicology studies easier.
Subscribe to our email newsletter
Nanotechnologies have been proven as a valuable adjunct to the development of new therapeutics. Nanoparticles provide a much larger surface area thereby increasing the dissolution rate resulting in enhanced absorption. Nanosizing compound elicits improved drug loading, exposure and bioavailability, and faster onset (earlier Tmax).
The patented, proprietary nanosizing process used at MicroConstants does not involve water or mechanical shear, so it is faster and more efficient than aqueous-based technologies.
Furthermore, the process typically does not require the addition of excipients, leaving the pure Active Pharmaceutical Ingredient (API) ready for easy dispersion as a convenient suspension formulation. The cost effective technique provides higher dose loading (50-60%), and is amendable to all routes of extravascular administration. The particle size is reproducible and the process is completely scalable.